FindTrial
Sign In

Pulmonary Vein Isolation Outcomes With Fish Oils

Pulmonary Vein Isolation Outcomes With Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid (DHA)

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT00841451
Acronym
PUFA
Enrollment
Unknown
Registered
2009-02-11
Start date
Unknown
Completion date
Unknown
Last updated
2016-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

Atrial Fibrillation, Persistent, Paroxysmal, Pulmonary Vein isolation, Omega three fatty acids, Fish Oils

Brief summary

Fish oil therapy may decrease the incidence of cardiac arrhythmias. This study will test whether pre-treatment with fish oils before catheter ablation of atrial fibrillation decreases the early post operative occurrence of atrial fibrillation.

Interventions

DRUGLovaza (Fish Oils)

Double blinded placebo controlled

Sponsors

GlaxoSmithKline
CollaboratorINDUSTRY
St. Luke's-Roosevelt Hospital Center
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Paroxysmal Atrial fibrillation (PAF). * Persistent atrial fibrillation. Persistent AF is not self-limited.

Exclusion criteria

* Previous pulmonary vein isolation ablation procedure * Contraindication for anticoagulation * Permanent AF * Severe valvular pathology * Concurrent use of antiarrhythmic medications * Inability to give consent * Pregnancy

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026